Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cancer: early-phase trial registry
279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #6 of 28,707 conditions by registered trial count.
621 US clinical trials · 279 currently recruiting · #6 of 28,707 conditions by registered trial count
Cancer: 621 US clinical trials tracked, 279 recruiting.
Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition cancer
OPEN 279 | RECR 45% | LATE 31 | EARLY 164 | RANK #6 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Duchenne Muscular Dystrophy (45% recruiting · 49 trials)
Cancer lists 279 open slots (45% of 621 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cancer is recruiting above its size-band peers.
279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.
-
Typical Cancer enrolment sits around 108 participants.
Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.
-
Cancer research is mostly interventional.
462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
621 total, page 12 of 13
CancerLife: Patient-Driven Solution in Cancer Care
Saint John's Cancer Institute
NCT03371147
A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression
National Cancer Institute (NCI)
NCT00928382
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
New York Presbyterian Brooklyn Methodist Hospital
NCT00374751
Eribulin and Lenvatinib in Advanced Solid Tumors
Virginia G. Kaklamani
NCT02640508
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
GlaxoSmithKline
NCT01966445
Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors
Emory University
NCT03539835
Post-Operative Ambulatory Challenge and Exercise (PACE) Trial
Dana-Farber Cancer Institute
NCT03234933
Improving Care Coordination for Adolescents and Young Adults With Cancer
Wake Forest University Health Sciences
NCT04586127
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
University of Utah
NCT00708448
High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
M.D. Anderson Cancer Center
NCT02932332
M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program
M.D. Anderson Cancer Center
NCT00827801
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
Myrexis
NCT00920205
Virtual Reality to Promote Relaxation Prior to Simulation
Abramson Cancer Center at Penn Medicine
NCT06318338
A Study of AMG 820 in Subjects With Advanced Solid Tumors
AmMax Bio
NCT01444404
Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
New Mexico Cancer Research Alliance
NCT00322634
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
NCT00082823
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00094562
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
AEterna Zentaris
NCT01224730
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
GlaxoSmithKline
NCT01954043
An Open Label Study of Oral Enzastaurin in Participants With Cancer
Eli Lilly and Company
NCT00309140
A Brief Parental Intervention on Learning and Education in Childhood Cancer
University of New Mexi
NCT05268315
Study of Irinotecan on a Weekly Schedule in Children
Baylor College of Medicine
NCT00062842
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
Soricimed Biopharma
NCT01578564
Faith-Based African American Cancer Survivorship Storytelling
Emory University
NCT03082612
INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.
University of New Mexi
NCT00276003
Bintrafusp Alfa Program Rollover Study
EMD Serono Research & Development Institute
NCT05061823
Behavioral Activation-Led Activity Engagement for Cancer Empowerment
University of Pittsburgh
NCT06796608
Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan
University of New Mexi
NCT00249977
Learning Yoga to eNhance Cancer Survivorship
Northwestern University
NCT04301050
Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer
University of California, Davis
NCT04594096
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
NCT00509691
Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial
Cedars-Sinai Medical Center
NCT05403736
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Esanex
NCT02063958
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
Genentech
NCT02536391
Mindfulness Based Smoking Cessation Program
Boston Medical Center
NCT02795312
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
NCT03495323
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
NCT01235897
Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assess
H. Lee Moffitt Cancer Center and Research Institute
NCT00822822
Traditional African Healing Ceremony in a U.S. Population
Duke University
NCT01873482
Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists'Communication Styles
Memorial Sloan Kettering Cancer Center
NCT00582192
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Esanex
NCT01851096
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
MedImmune
NCT00284817
Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer
University of Miami
NCT03993054
Topotecan Pharmacokinetic Characterization Study
GlaxoSmithKline
NCT00361803
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
University of Utah
NCT00707343
Combination Paclitaxel, Carboplatin and Temozolomide
New Mexico Cancer Research Alliance
NCT00249964
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
National Cancer Institute (NCI)
NCT00061347
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Albert Einstein College of Medicine
NCT03403049
Influence of Adiposity on IGF-1 and Fitness Response to Exercise in Cancer Survivors
University of Colorado, Denver
NCT05558384
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Cellectar Biosciences
NCT01495663
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 116 |
| Phase 2 | 48 |
| Phase 3 | 27 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cancer page
621 registered trials, 279 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 279 Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer condition card totals 621 registered trials; most-linked intervention Usual Care; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.